

A. FURTHER INFORMATION ABOUT OUR COMPANY AND OUR SUBSIDIARIES**1. Incorporation**

Our Company was incorporated as a private company limited by shares in Hong Kong under the Companies Ordinance on November 30, 2015 under the name of Sound & Sincere Investment Limited (興聲投資有限公司). The name of our Company was changed to Simcere Pharmaceutical (Hong Kong) Limited (先聲藥業(香港)有限公司) on January 16, 2019 and was further changed to Simcere Pharmaceutical Group Limited (先聲藥業集團有限公司) on June 17, 2019. Our registered office is at 43/F, AIA Tower, 183 Electric Road, North Point, Hong Kong.

As our Company was incorporated in Hong Kong, we operate subject to the Companies Ordinance, the Companies (Winding Up and Miscellaneous Provisions) Ordinance and our Articles of Association. A summary of the Articles of Association is set forth in Appendix IV to this prospectus.

2. Changes in the share capital of our Company

On the date of incorporation, our Company allotted and issued one Share to SPHL. The following sets out the alterations in the share capital of our Company since the date of its incorporation:

- (i) On December 31, 2017, our Company allotted and issued 39,999 Shares to SPHL.
- (ii) On June 21, 2019, our Company allotted and issued an aggregate of 2,345,077,618 new Shares. The details of the subscribers are as follows:

Name of Shareholder	Number of Issued Shares
SPHL	1,195,969,986
Artking	606,810,031
EGG	130,669,050
FFI	120,961,370
Premier Praise	114,986,405
King View	57,918,000
Excel Management	54,719,407
Fosun Industrial	43,600,629
Palace Investments	19,442,740
Total	<u>2,345,077,618</u>

- (iii) On April 15, 2020, EGG transferred 9,263,736 Shares of our Company to each of CNCB HK and CNCB SPC (acting on behalf of CNCB Investment), respectively. Upon completion of such transfer, the shareholding structure of our Company is as follows:

Name of Shareholder	Number of Issued Shares
SPHL	1,196,009,986
Artking	606,810,031
FFI	120,961,370
Premier Praise	114,986,405
EGG	112,141,578
King View	57,918,000
Excel Management	54,719,407
Fosun Industrial	43,600,629
Palace Investments	19,442,740
CNCB HK	9,263,736
CNCB SPC (acting on behalf of CNCB Investment)	9,263,736
Total	<u>2,345,117,618</u>

- (iv) Assuming the Global Offering becomes unconditional and the issue of Shares is made pursuant thereto (assuming that the Over-allotment Option is not exercised), the share capital of our Company immediately following the completion of the Global Offering will comprise 2,605,686,618 Shares.
- (v) Assuming the Global Offering becomes unconditional and the issue of Shares is made pursuant thereto (assuming that the Over-allotment Option is exercised in full), the share capital of our Company immediately following the completion of the Global Offering will comprise 2,644,771,618 Shares.

Save as disclosed above, there has been no change in our share capital within the two years immediately preceding the date of this prospectus.

3. Resolutions in writing of our Shareholders passed on October 8, 2020

Pursuant to the written resolutions passed by our Shareholders on October 8, 2020, it was resolved, among others:

- (a) our Company approved and adopted the Articles of Association with effect from the date of the Hong Kong Underwriting Agreement;
- (b) conditional on (i) the Listing Committee of the Stock Exchange granting the approval for the listing of, and permission to deal in, the Shares in issue and Shares to be issued, (ii) the Offer Price being determined, and (iii) the obligations of the Underwriters under the Underwriting Agreements becoming unconditional and the Underwriting Agreements not being terminated in accordance with their terms or otherwise:
 - (i) the Global Offering and the Over-allotment Option were approved and our Directors were authorized to effect the same and to allot and issue the Offer Shares pursuant to the Global Offering and the Over-allotment Option;
 - (ii) the grant of the Over-allotment Option by our Company to the International Underwriters, exercisable by the Joint Global Coordinators, pursuant to which the Joint Global Coordinators (on behalf of the International Underwriters) may require our Company to allot and issue up to an aggregate of additional 39,085,000 Shares to cover, among others, the over-allocation in the International Offering was approved; and
 - (iii) the proposed Listing was approved and our Directors were authorized to implement the Listing.
- (c) a general unconditional mandate was granted to the Directors to allot, issue and deal with Shares or securities convertible into Shares or options, warrants or similar rights to subscribe for Shares or such convertible securities and to make or grant offers, agreements or options which would or might require the exercise of such powers, provided that number of Shares allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors other than pursuant to (i) a rights issue, (ii) any scrip dividend scheme or similar arrangement providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the Articles of Association, and (iii) a specific authority granted by the shareholders of the Company in general meeting, shall not exceed the aggregate of 20% of the total number of the Shares of the Company in issue immediately following the completion of the Global Offering (but excluding any Shares which may be issued pursuant to the exercise of the Over-allotment Option), such mandate to remain in effect during the period from the passing of the resolution until the earliest of (i) the conclusion of our next annual general meeting; (ii) the expiration of the period within which we are required by

any applicable law or the Articles of Association to hold our next annual general meeting; or (iii) the date on which the resolution is varied or revoked by an ordinary resolution of the Shareholders in general meeting (the “**Applicable Period**”);

- (d) a general unconditional mandate was granted to the Directors to exercise all powers of our Company to repurchase on the Stock Exchange or on any other stock exchange on which the securities of our Company may be listed and which is recognized by the SFC and the Stock Exchange for this purpose, of Shares with a total number of not more than 10% of the total number of the Shares of the Company in issue immediately following the completion of the Global Offering (but excluding any Shares which may be issued pursuant to the exercise of the Over-allotment Option), such mandate to remain in effect during the Applicable Period; and
- (e) the general unconditional mandate mentioned in paragraph (c) above be extended by the addition to the total number of issued Shares of our Company which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to such general mandate of an amount representing the total number of issued Shares of our Company repurchased by our Company pursuant to the mandate to repurchase Shares referred to in (d) above, provided that such extended amount shall not exceed 10% of the total number of Shares in issue immediately following the completion of the Global Offering (but excluding any Shares which may be issued pursuant to the exercise of the Over-allotment Option).

4. Corporate reorganization

The companies comprising our Group underwent the Reorganization in preparation for the Listing. For further details, see “History, Reorganization and Corporate Structure – Reorganization.”

5. Changes in the share capital of our subsidiaries and Consolidated Affiliated Entity

A summary of the corporate information and the particulars of our subsidiaries are listed in the Accountants’ Report as set out in Appendix I to this prospectus.

Save as disclosed in “History, Reorganization and Corporate Structure” and below, there has been no alteration in the share capital or the registered capital of any of our subsidiaries or our Consolidated Affiliated Entity within the two years immediately preceding the date of this prospectus:

Shanghai Xianyi

On September 11, 2018, the registered capital of Shanghai Xianyi was increased from RMB10,000,000 to RMB468,000,000.

Sincere Shanghai Pharmaceutical

On September 26, 2019, the registered capital of Sincere Shanghai Pharmaceutical was increased from RMB20,000,000 to RMB250,000,000.

Nanjing BioSciKin

On December 13, 2018, Nanjing BioSciKin was established in the PRC with an initial registered capital of RMB5,000,000.

On August 30, 2019, the registered capital of Nanjing BioSciKin increased from RMB5,000,000 to RMB46,660,000.

Sincere Innovation

On March 22, 2019, Sincere Innovation was incorporated in the State of Delaware, the United States with 1,000 shares of common stock with par value of USD0.001 per share.

Simgene Group

On April 9, 2020, Simgene Group was incorporated in the Cayman Islands with one share issued to Mapcal Limited with a par value of USD1.00 each. Mapcal Limited subsequently transferred the one share to our Company on the same date.

Shanghai Xianjing

On April 23, 2020, Shanghai Xianjing was established in the PRC with an initial registered capital of USD1,000,000.

Shanghai Xianbo

On April 22, 2020, Shanghai Xianbo was established in the PRC with an initial registered capital of RMB1,000,000.

6. Repurchase of Shares by our Company

This section sets out information required by the Stock Exchange to be included in this prospectus concerning the repurchase by the Company of its own securities.

(a) *Provisions of the Listing Rules*

The Listing Rules permit companies whose primary listings are on the Main Board of the Stock Exchange to repurchase their securities on the Stock Exchange subject to certain restrictions, the most important of which are summarized below:

(i) *Shareholders' approval*

All proposed repurchases of securities on the Stock Exchange by a company with a primary listing on the Stock Exchange must be approved in advance by an ordinary resolution of shareholders, either by way of general mandate or by specific approval of a particular transaction.

Pursuant to the resolutions in writing of our Shareholders passed on October 8, 2020, a general unconditional mandate (the “**Repurchase Mandate**”) was granted to our Directors authorizing the repurchase by our Company on the Stock Exchange, or on any other stock exchange on which the securities of our Company may be listed and which is recognized by the SFC and the Stock Exchange for this purpose, of Shares with a total number not exceeding 10% of the total number of Shares of our Company in issue immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), at any time until the conclusion of the next annual general meeting of our Company, the expiration of the period within which the next annual general meeting of our Company is required by any applicable law or the Articles of Association to be held or when such mandate is revoked or varied by an ordinary resolution of our Shareholders in general meeting, whichever is the earliest.

(ii) *Source of funds*

Repurchases must be funded out of funds legally available for the purpose in accordance with the Articles of Association and the applicable laws of the Hong Kong. A listed company may not repurchase its own securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange as amended from time to time.

(iii) *Trading restrictions*

The total number of shares which a listed company may repurchase on the Stock Exchange is the number of shares representing up to a maximum of 10% of the aggregate number of shares in issue. A listed company may not issue or announce a proposed issue of new securities for a period of 30 days immediately following a repurchase (other than an issue of securities pursuant to an exercise of warrants, share options or similar instruments requiring the company to issue securities which were outstanding prior to such repurchase) without the prior

approval of the Stock Exchange. In addition, a listed company is prohibited from repurchasing its shares on the Stock Exchange if the purchase price is 5% or more than the average closing market price for the five preceding trading days on which its shares were traded on the Stock Exchange.

The Listing Rules also prohibit a listed company from repurchasing its securities on the Stock Exchange if the repurchase would result in the number of listed securities which are in the hands of the public falling below the relevant prescribed minimum percentage as required by the Stock Exchange.

A listed company is required to procure that the broker appointed by it to effect a repurchase of securities disclose to the Stock Exchange such information with respect to the repurchase made on behalf of the listed company as the Stock Exchange may require.

(iv) Status of repurchased shares

All repurchased shares (whether effected on the Stock Exchange or otherwise) will be automatically delisted and the certificates for those shares must be cancelled and destroyed.

(v) Suspension of repurchase

A listed company may not make any repurchase of securities after inside information has come to its knowledge until the information has been made publicly available. In particular, during the period of one month immediately preceding the earlier of (a) the date of the board meeting (as such date is first notified to the Stock Exchange in accordance with the Listing Rules) for the approval of a listed company's results for any year, half-year, quarterly or any other interim period (whether or not required under the Listing Rules) and (b) the deadline for a listed company to announce its results for any year or half-year under the Listing Rules, or quarterly or any other interim period (whether or not required under the Listing Rules) and ending on the date of the results announcement, the listed company may not repurchase its securities on the Stock Exchange other than in exceptional circumstances. In addition, the Stock Exchange may prohibit a repurchase of shares on the Stock Exchange if a listed company has breached the Listing Rules.

(vi) Reporting requirements

Certain information relating to repurchases of securities on the Stock Exchange or otherwise must be reported to the Stock Exchange not later than 30 minutes before the earlier of the commencement of the morning trading session or any pre-opening session on the following Business Day. In addition, a listed company's annual report is required to disclose details regarding repurchases of securities made

during the year reviewed, including a monthly analysis of the number of securities repurchased, the purchase price per share or the highest and lowest price paid for all such purchases, where relevant, and the aggregate prices paid.

(vii) Core connected persons

A listed company is prohibited from knowingly repurchasing securities on the Stock Exchange from a “core connected person,” that is, a director, chief executive or substantial shareholder of the company or any of its subsidiaries or their respective close associates and a core connected person is prohibited from knowingly selling his securities to the company, on the Stock Exchange.

(b) Reasons for repurchases

Our Directors believe that it is in the best interests of our Company and Shareholders for our Directors to receive the general authority from our Shareholders to repurchase Shares in the market. Repurchases of Shares will only be made when our Directors believe that such repurchases will be in the interest of our Company and our Shareholders. Such repurchases may, depending on market conditions, funding arrangements and other circumstances at the time, lead to an enhancement of the net value of our Company and its assets and/or its earnings per Share.

(c) Funding of repurchases

In repurchasing securities, our Company may only apply funds legally available for such purpose in accordance with the Articles of Association, the Listing Rules and the applicable laws of Hong Kong.

Any payment for the repurchase of Shares will be drawn from the profits or share premium of our Company or from the proceeds of a fresh issue of shares made for the purpose of the repurchase or out of capital and, in the case of any premium payable on the purchase, out of the profits of our Company or from sums standing to the credit of the share premium account of our Company.

Our Directors do not propose to exercise the Repurchase Mandate to such an extent as would, under the circumstances, have a material adverse effect in the opinion of our Directors on the working capital requirements of our Company or our gearing levels. However, there might be a material adverse impact on the working capital or gearing position of our Company as compared with the position disclosed in this prospectus in the event that the Repurchase Mandate is exercised in full.

(d) Share capital

The exercise in full of the Repurchase Mandate, on the basis of 2,605,686,618 Shares in issue immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), could accordingly result in up to 260,568,661 Shares being repurchased by our Company during the period until:

- (i) the conclusion of the next annual general meeting of our Company;
- (ii) the expiration of the period within which the next annual general meeting of our Company is required by any applicable law or the Articles of Association to be held; or
- (iii) the date on which the Repurchase Mandate is revoked or varied by an ordinary resolution of our Shareholders in general meeting,

whichever is the earliest.

(e) General

None of our Directors or, to the best of their knowledge having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules), has any present intention to sell any Shares to our Company or our subsidiaries.

Our Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws and regulations from time to time in force in Hong Kong. Our Company has not repurchased any Shares since our incorporation.

No core connected person (as defined in the Listing Rules) of our Company has notified our Company that he/she or it has a present intention to sell Shares to our Company, or has undertaken not to do so, if the Repurchase Mandate is exercised.

If as a result of a securities repurchase pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of our Company increases, such increase will be treated as an acquisition for the purpose of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert, depending on the level of the increase of our Shareholders' interest, could obtain or consolidate control of our Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code as a result. Save as aforesaid, our Directors are not aware of any consequences which may arise under the Takeovers Code if the Repurchase Mandate is exercised. Any repurchase of Shares which results in the number of Shares held by the public being reduced to less than prescribed percentage of our Shares then in issue could only be implemented with the approval of the Stock Exchange to waive the Listing Rules requirements regarding the public shareholding referred to above. It is believed that a waiver of this provision would not normally be given other than in exceptional circumstances.

B. FURTHER INFORMATION ABOUT OUR BUSINESS**1. Summary of material contracts**

The following contracts (not being contracts entered into in the ordinary course of our business) have been entered into by us within the two years preceding the date of this prospectus and are or may be material:

- (a) a supplemental agreement dated April 8, 2020 entered into among Excel Good Group Limited, CNCB (Hong Kong) Investment Limited, CNCB Capital Value SPC (acting on behalf of CNCB Capital Opportunity Investment Fund SP) and our Company, pursuant to which certain special rights were granted to CNCB (Hong Kong) Investment Limited and CNCB Capital Value SPC (acting on behalf of CNCB Capital Opportunity Investment Fund SP) with respect to their shareholding in our Company;
- (b) an exclusive business cooperation agreement dated April 30, 2020 entered into between Shanghai Xianjing Biological Technology Co., Ltd. (上海先競生物科技有限公司) and Shanghai Xianbo Biological Technology Co., Ltd. (上海先博生物科技有限公司), as further described in the section headed “Contractual Arrangements;”
- (c) an exclusive option agreement dated April 30, 2020 entered into among Shanghai Xianjing Biological Technology Co., Ltd. (上海先競生物科技有限公司), Mr. Ren Jinsheng (任晉生), Mr. Zhu Zhenfei (朱振飛) and Shanghai Xianbo Biological Technology Co., Ltd. (上海先博生物科技有限公司), as further described in the section headed “Contractual Arrangements;”
- (d) an equity pledge agreement dated April 30, 2020 entered into among Shanghai Xianjing Biological Technology Co., Ltd. (上海先競生物科技有限公司), Mr. Ren Jinsheng (任晉生), Mr. Zhu Zhenfei (朱振飛) and Shanghai Xianbo Biological Technology Co., Ltd. (上海先博生物科技有限公司), as further described in the section headed “Contractual Arrangements;”
- (e) a shareholder’s rights entrustment agreement dated April 30, 2020 entered into among Shanghai Xianjing Biological Technology Co., Ltd. (上海先競生物科技有限公司), Mr. Ren Jinsheng (任晉生), Mr. Zhu Zhenfei (朱振飛) and Shanghai Xianbo Biological Technology Co., Ltd. (上海先博生物科技有限公司), as further described in the section headed “Contractual Arrangements;”
- (f) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, Gaoling Fund, L.P., YHG Investment, L.P., Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited and UBS AG Hong Kong Branch, details of which are included in the section headed “Cornerstone Investors;”

- (g) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, Lake Bleu Prime Healthcare Master Fund Limited, Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;”
- (h) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, Jericho Capital Master Fund L.P., Jericho Asia Opportunities Master LP, Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;”
- (i) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, Sage Partners Master Fund, Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;”
- (j) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, OrbiMed Partners Master Fund Limited, Worldwide Healthcare Trust PLC, OrbiMed Genesis Master Fund, L.P., OrbiMed New Horizons Master Fund, L.P., Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;”
- (k) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, New & High (HK) Limited, Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;”
- (l) a cornerstone investment agreement dated October 8, 2020 entered into among our Company, Red Earth Innovation International Company Limited, Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited, details of which are included in the section headed “Cornerstone Investors;” and
- (m) the Hong Kong Underwriting Agreement.

2. Intellectual property rights of our Group

(a) Trademarks

As of the Latest Practicable Date, we were the registered owner of and had the right to use the following trademarks which we consider to be or may be material to our business:

No.	Name of Registered Proprietor	Trademark	Place of Registration	Registration Number	Class	Expiry Date
1.	Jiangsu Simcere	英太青	PRC	800117	5	2025-12-20
2.	Jiangsu Simcere	英太青	PRC	1375206	5	2030-03-20
3.	Jiangsu Simcere	法能	PRC	1134665	5	2027-12-13
4.	Jiangsu Simcere	诺威	PRC	6243129	5	2030-11-06
5.	Jiangsu Simcere	欣他	PRC	1360256	5	2030-02-06
6.	Jiangsu Simcere	欣他	PRC	6243127	5	2030-03-13
7.	Jiangsu Simcere	YINGTAIQING	PRC	1708410	5	2022-02-06
8.	Jiangsu Simcere	舒夫坦	PRC	3690536	5	2025-12-27
9.	Jiangsu Simcere		PRC	16201819	5, 35	2026-04-06
10.	Jiangsu Simcere	ENDU	PRC	6021079	5	2030-03-06
11.	Jiangsu Simcere	Newanti	PRC	6439801	5	2030-03-27
12.	Jiangsu Simcere		PRC	7984034	5	2022-10-20
13.	Jiangsu Simcere	恩立施	PRC	42014291	5	2030-08-06
14.	Jiangsu Simcere		PRC	40526637	5	2030-04-13
15.	Jiangsu Simcere	恩立施	PRC	20968713	5	2027-10-06
16.	Jiangsu Simcere	NUOWEI	PRC	22717554	5	2028-02-20
17.	Jiangsu Simcere	XINTA	PRC	22717556	5	2028-02-20
18.	Jiangsu Simcere	FANENG	PRC	22717557	5	2028-04-06
19.	Jiangsu Simcere	SHUFUTAN	PRC	22717555	5	2028-02-20
20.	Wuhu Simcere	中人氟安	PRC	3272952	5	2024-05-20
21.	Wuhu Simcere	SinoFuan	PRC	3272951	5	2024-01-06
22.	Wuhu Simcere	ZHONGRENFUAN	PRC	22966923	5	2028-02-27
23.	Shandong Simcere	恩度	PRC	4209867	5	2027-08-06
24.	Shandong Simcere	endostar	PRC	4209870	5	2027-10-20
25.	Shandong Simcere		PRC	5969144	5	2030-01-13
26.	Shandong Simcere	恩度	PRC	6776881	5	2030-06-06
27.	Simcere Pharmaceutical	也青	PRC	13461499	5	2025-01-27

No.	Name of Registered Proprietor	Trademark	Place of Registration	Registration Number	Class	Expiry Date
28.	Sincere Pharmaceutical		PRC	3380330	5	2024-07-13
29.	Sincere Pharmaceutical	捷佰舒	PRC	6963303	5	2030-09-27
30.	Sincere Pharmaceutical	捷佰立	PRC	4850025	5	2029-01-13
31.	Sincere Pharmaceutical		PRC	6915006	5	2030-10-06
32.	Sincere Pharmaceutical	BICUN	PRC	22717451	5	2028-02-20
33.	Sincere Pharmaceutical	JIEBAISHU	PRC	22717447	5	2028-02-20
34.	Sincere Pharmaceutical	DINGAN	PRC	22717450	5	2028-02-20
35.	Sincere Pharmaceutical	YEQING	PRC	22717445	5	2028-04-06
36.	Sincere Pharmaceutical	ANQI	PRC	22717553	5	2028-04-20
37.	Sincere Pharmaceutical	必存	PRC	1732434	5	2022-03-20
38.	Sincere Pharmaceutical	安信	PRC	1014734	5	2027-05-27
39.	Sincere Pharmaceutical	再奇	PRC	924717	5	2027-01-06
40.	Sincere Pharmaceutical	ANXIN	PRC	33762074	5	2029-06-06
41.	Sincere Pharmaceutical	先必新	PRC	6317286	5	2030-03-27
42.	Hainan Sincere	安立青	PRC	719691	5	2024-12-13
43.	Hainan Sincere	再林	PRC	719695	5	2024-12-13
44.	Hainan Sincere	再立克	PRC	920725	5	2026-12-27
45.	Hainan Sincere	再克	PRC	924719	5	2027-01-06
46.	Hainan Sincere	再畅	PRC	924724	5	2027-01-06
47.	Hainan Sincere	顶安	PRC	1014732	5	2027-05-27
48.	Hainan Sincere	必奇	PRC	1134663	5	2027-12-13
49.	Hainan Sincere	欧迪佳	PRC	1280222	5	2029-06-06
50.	Hainan Sincere	艾得辛	PRC	1360255	5	2030-02-06
51.	Hainan Sincere	尤舒	PRC	1552482	5	2021-04-13
52.	Hainan Sincere	力宏	PRC	1907148	5	2022-09-20
53.	Hainan Sincere	必奇	PRC	3010723	5	2022-12-13
54.	Hainan Sincere	ZAILIN	PRC	3440799	5	2028-02-20
55.	Hainan Sincere	再林	PRC	3606808	5	2025-12-13

No.	Name of Registered Proprietor	Trademark	Place of Registration	Registration Number	Class	Expiry Date
56.	Hainan Simcere	再林 ZAILIN	PRC	4086025	5	2027-03-20
57.	Hainan Simcere		PRC	5036399	5	2029-04-27
58.	Hainan Simcere		PRC	5036400	5	2029-04-27
59.	Hainan Simcere	艾得辛	PRC	6177291	5	2030-02-27
60.	Hainan Simcere	Aidexin	PRC	10053468	5	2022-12-13
61.	Hainan Simcere		PRC	10102311	5	2023-01-06
62.	Hainan Simcere	IREMOD	PRC	22717432	5	2028-02-20
63.	Hainan Simcere	ZAILIKE	PRC	22717433	5	2028-02-20
64.	Hainan Simcere	ZAIKE	PRC	22717434	5	2028-02-20
65.	Hainan Simcere	ZAICHANG	PRC	22717436	5	2028-02-20
66.	Hainan Simcere	YOU SHU	PRC	22717437	5	2028-04-06
67.	Hainan Simcere	OU DI JIA	PRC	22717439	5	2028-02-20
68.	Hainan Simcere	BIQI	PRC	22717442	5	2028-04-06
69.	Hainan Simcere	AN LI QING	PRC	22717444	5	2028-02-20
70.	Hainan Simcere	顶安	PRC	24925394	5	2028-07-06
71.	Hainan Simcere	安奇	PRC	1014731	5	2027-05-27
72.	Hainan Simcere	安奇	PRC	25345339	5	2028-10-13
73.	Jiangsu Simcere		United States	5107097	5	2025-07-23
74.	Jiangsu Simcere		European Union	1285916	5	2025-07-23
75.	Shandong Simcere	恩度	Hong Kong	301159920	5	2028-07-13
76.	Shandong Simcere	恩度	Taiwan	01357581	5	2029-04-15
77.	Shandong Simcere	恩度	Japan	5218286	5	2029-03-27
78.	Shandong Simcere	恩度	Macao	N/038114	5	2023-02-02
79.	Hainan Simcere		Hong Kong	303661182	16	2026-01-17
80.	Sincere Pharmaceutical	安适	PRC	972695	5	2027-04-06

(b) Patents

As of the Latest Practicable Date, we have registered the following patents in the PRC:

(i) Patents concerning our major products

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
1	Bicun	Sincere Pharmaceutical	Edaravone injection and preparation process thereof	ZL201010264768.1	Invention	2010-08-26	2030-08-25
2	Bicun; Sanbexin	Jiangsu Sincere; Sincere Pharmaceutical	Phenyl pyrazole compound and preparation method and application thereof	ZL201410725327.5	Invention	2014-12-03	2034-12-02
3	Bicun	Jiangsu Sincere; Sincere Pharmaceutical	New use of 3-methyl-1-phenyl-2-pyrazoline-5-ketone	ZL201110046506.2	Invention	2011-02-26	2031-02-25
4	Bicun; Sanbexin	Jiangsu Sincere; Sincere Pharmaceutical	Synthesis process of edaravone metabolite	ZL200910264437.5	Invention	2009-12-22	2029-12-21
5	Bicun	Jiangsu Sincere; Sincere Pharmaceutical	Edaravone lyophilized preparation and preparation technique thereof	ZL200810123767.8	Invention	2008-06-04	2028-06-03
6	Bicun; Sanbexin	Jiangsu Sincere; Sincere Pharmaceutical; Jilinsheng Boda Pharmaceutical Co., Ltd.	Pyrazolines compound as well as application and preparation method thereof	ZL201010156628.2	Invention	2010-04-27	2030-04-26
7	Bicun	Jiangsu Sincere; Sincere Pharmaceutical; Jilinsheng Boda Pharmaceutical Co., Ltd.	New use of edaravone	ZL200510095061.1	Invention	2005-10-28	2025-10-27
8	Jepaso	Sincere Pharmaceutical	Process for refining Nedaplatin	ZL200710022407.4	Invention	2007-05-17	2027-05-16
9	ZAILIN	Hainan Sincere	Amoxicillin particle and preparation process thereof	ZL201010556659.7	Invention	2010-11-24	2030-11-23
10	ZAILIN	Hainan Sincere	Package (ZAILIN Amoxicillin in granules)	ZL201930672536.1	Appearance design	2019-12-03	2029-12-02

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
11	ZAILIN	Hainan Simcere	Package (Amoxicillin dispersible tablets – Zailin)	ZL201530112246.3	Appearance design	2015-04-23	2025-04-22
12	Endostar	Jiangsu Simcere	Medicinal composition and application thereof	ZL201010182183.5	Invention	2010-05-25	2030-05-24
13	Endostar	Jiangsu Simcere	Method for preparing small-granularity recombination human vascular endothelium inhibin slowly-released particle for injection	ZL200910231612.0	Invention	2009-12-10	2029-12-09
14	Endostar	Jiangsu Simcere	Injection-use recombinant human Endostatin porous sustained-release microsphere and preparation method thereof	ZL200810019876.5	Invention	2008-03-20	2028-03-19
15	Endostar	Jiangsu Simcere	Recombinant human endostatin sustained-release injection oil preparation and preparation process thereof	ZL201110101864.9	Invention	2007-11-08	2027-11-07
16	Endostar	Shandong Simcere	Preparation method of recombined human blood-vessel endothelial inhibin sustained-released microsphere	ZL200710132290.5	Invention	2007-09-27	2027-09-26
17	Endostar	Jiangsu Simcere; Shandong Simcere	Method for detecting biological activity of recombinant human endostatin	ZL201710019912.7	Invention	2017-01-12	2037-01-11
18	Endostar	Jiangsu Simcere; Shandong Simcere	Stable rhEndostatin subcutaneous injection composition	ZL201610860508.8	Invention	2016-09-28	2036-09-27
19	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing porous gel containing recombinant human endostatin	ZL201210235031.6	Invention	2012-07-09	2032-07-08

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
						Date	Expiry Date
20	Endostar	Jiangsu Simcere; Shandong Simcere	Recombinant human endostatin temperature-sensitive gel composition for injection	ZL201010274209.9	Invention	2010-09-07	2030-09-06
21	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing chitosan nanoparticles with recombinant human endostar for injection	ZL201010231316.3	Invention	2010-07-20	2030-07-19
22	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing chitosan nanoparticles	ZL201010231319.7	Invention	2010-07-20	2030-07-19
23	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing recombinant human endostatin chitosan nanoparticles for injection	ZL201010231337.5	Invention	2010-07-20	2030-07-19
24	Endostar	Jiangsu Simcere; Shandong Simcere	Pharmaceutical composition containing micronized human vascular endostatin	ZL200810122763.8	Invention	2008-06-30	2028-06-29
25	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing sustained-release microspheres containing micronized recombinant human vascular endothelial inhibin	ZL200810122764.2	Invention	2008-06-30	2028-06-29
26	Endostar	Jiangsu Simcere; Shandong Simcere	Method for preparing micronized protein	ZL200810122765.7	Invention	2008-06-30	2028-06-29
27	Endostar	Jiangsu Simcere; Shandong Simcere	Recombinant human vascular endothelial inhibitor sustained-release injection oil formulation and preparation thereof	ZL200710135101.X	Invention	2007-11-08	2027-11-07
28	Endostar	Jiangsu Simcere; Shandong Simcere	Process for producing recombinant human vascular endothelial inhibitor composition sustained-release microsphere	ZL200710135102.4	Invention	2007-11-08	2027-11-07

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
						Date	Expiry Date
29	Endostar	Jiangsu Simcere; Shandong Simcere	Recombined human blood vessel endothelial inhibin sustained-release injection composition	ZL200710132804.7	Invention	2007-09-30	2027-09-29
30	Endostar	Jiangsu Simcere; Shandong Simcere	Recombined human vascellum esoderma inhibin durative action preparation, preparation method and application thereof	ZL200710021667.X	Invention	2007-04-23	2027-04-22
31	Endostar	Jiangsu Simcere; Shandong Cancer Hospital & Institute	Recombinant human endostatin developer and its preparation method	ZL201210532923.2	Invention	2012-12-11	2032-12-10
32	Jiebaili	Jiangsu Simcere; Simcere Pharmaceutical	Pemetrexed disodium pharmaceutical composition and preparation method thereof	ZL201610828428.4	Invention	2016-09-18	2036-09-17
33	Softan	Jiangsu Simcere; Simcere Pharmaceutical	Rosuvastatin calcium medicine composition and preparation method thereof	ZL201610824497.8	Invention	2016-09-14	2036-09-13
34	Softan	Simcere Pharmaceutical; Jiangsu Simcere	Package (Rosuvastatin Calcium Tablets-Softan)	ZL201830599237.5	Appearance design	2018-10-25	2028-10-24
35	Iremod	Jiangsu Simcere; Hainan Simcere	Ailamode analogue and separation method thereof	ZL200910025605.5	Invention	2009-03-04	2029-03-03
36	Iremod	Jiangsu Simcere; China Pharmaceutical University	Igutimod slow release multielement composition and preparation method thereof	ZL201310124889.X	Invention	2013-04-11	2033-04-10
37	Iremod	Jiangsu Simcere; Hainan Simcere; Tianjin Institute of Pharmaceutical Research Co., Ltd.	Iguratimod crystal form and its composition	ZL200510015340.2	Invention	2005-10-09	2025-10-08

No.	Related	Name of	Patent Name	Patent Number	Class of	Application	
	Products of	Registered				Patent	Date
	Our Group	Proprietor					
38	Iremod	Jiangsu Simcere; Hainan Simcere; Tianjin Institute of Pharmaceutical Research Co., Ltd.	Iguratimod crystalline form and composite thereof	ZL201010236651.2	Invention	2005-10-09	2025-10-08
39	Iremod	Jiangsu Simcere; Hainan Simcere; Tianjin Institute of Pharmaceutical Research Co., Ltd.	Iguratimod crystal habit and composition thereof	ZL201010236615.6	Invention	2005-10-09	2025-10-08
40	Iremod	Jiangsu Simcere; Hainan Simcere; Tianjin Institute of Pharmaceutical Research Co., Ltd.	Iguratimod crystal habit and composition thereof	ZL201010236636.8	Invention	2005-10-09	2025-10-08
41	Iremod	Jiangsu Simcere; Hainan Simcere; Tianjin Institute of Pharmaceutical Research Co., Ltd.	Process for preparing colatemo solid preparation and its solid preparation	ZL03121088.0	Invention	2003-03-24	2023-03-23
42	Iremod	Hainan Simcere	Package (Iremod – iguratimod tablet)	ZL201230001612.4	Appearance design	2012-01-05	2022-01-04
43	Newanti	Jiangsu Simcere; Simcere Pharmaceutical	Biapenem dimer and preparation method thereof	ZL200710307231.7	Invention	2007-12-29	2027-12-28
44	Newanti	Jiangsu Simcere; Simcere Pharmaceutical	Improved Biapenem preparation method	ZL200610038044.9	Invention	2006-01-26	2026-01-25
45	Yingtaiqing	Hainan Simcere	Package (Antine – diclofenac sodium sustained-release capsules)	ZL201130050931.X	Appearance design	2011-03-22	2021-03-21
46	Yingtaiqing	Jiangsu Simcere	Package (Antine – diclofenac sodium sustained-release capsule)	ZL201730206665.2	Appearance design	2017-05-27	2027-05-26
47	Yingtaiqing	Jiangsu Simcere	Package (Antine – diclofenac sodium sustained-release capsule)	ZL201730004837.8	Appearance design	2017-01-06	2027-01-05

(ii) Patents concerning our other existing products

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
1	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	High-concentration injection of edaravone and natural borneol	ZL201510819604.3	Invention	2015-11-23	2035-11-22
2	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	Edaravone and (+)2-camphol liniment and preparation method thereof	ZL201510751056.5	Invention	2015-11-06	2035-11-05
3	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	New use of 3-methyl-1-phenyl-2-pyrazolin-5-ketone and 2-borneol composition	ZL201110230461.4	Invention	2011-08-12	2031-08-11
4	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	New application of composition of 3-methyl-1-phenyl-2-pyrazoline-5-ketone and borneol	ZL201110046673.7	Invention	2011-02-26	2031-02-25
5	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	Method for synthesizing sulfoacid organic compounds in one step	ZL201110025316.2	Invention	2011-01-24	2031-01-23
6	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	New application of 3-methyl-1-phenyl-2-pyrazoline-5-ketone and 2-borneol composition	ZL201110005363.0	Invention	2011-01-12	2031-01-11
7	Sanbexin	Jiangsu Simcere; Simcere Pharmaceutical	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	ZL200980100527.9	Invention	2009-03-03	2029-03-02
8	Zanamivir dry powder for inhalation (Yeqing)	Jiangsu Simcere	Preparation method of zanamivir impurity	ZL201410164580.8	Invention	2014-04-22	2034-04-21

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
9	Zanamivir dry powder for inhalation (Yeqing)	Jiangsu Simcere; Simcere Pharmaceutical	HPLC determination method for detecting impurities in zanamivir and zanamivir-containing preparation	ZL201310058607.0	Invention	2013-02-25	2033-02-24
10	Oxaliplatin for Injection (Jiexin)	Simcere Pharmaceutical	Method for preparing oxaliplatin with very low content of impurities	ZL200910263079.6	Invention	2009-12-16	2029-12-15
11	Subcutaneous PD-L1 monodomain antibody combined medicine – 1	Jiangsu Simcere	Method for determining biology activity of PD-1 pathway inhibitor	ZL201510039969.4	Invention	2015-01-26	2035-01-25
12	KeChuanNing Tablet (Simcere); KeChuanNing Oral Liquid (Simcere)	Jiangsu Simcere	Medicine for resolving sputum and relieving asthma and cough, preparing process thereof	ZL03152998.4	Invention	2003-09-12	2023-09-11
13	Levamlodipine besylate tablet (Xinta)	Jiangsu Simcere; Hainan Simcere	Method for preparing levamlodipine from racemic amlodipine maleate	ZL200910030828.0	Invention	2009-04-17	2029-04-16
14	Palonosetron Hydrochloride injection (Lowvo)	Jiangsu Simcere; Simcere Pharmaceutical	Preparation process of high-purity palonosetron Hcl	ZL200810122766.1	Invention	2008-06-30	2028-06-29
15	Dextromethorphan hydrobromide granules (Beitai)	Hainan Simcere	Package (Dextromethorphan Hydrobromide Granules – Beitai) (氢溴酸右美沙芬颗粒-貝泰)	ZL201530112128.2	Appearance design	2015-04-23	2025-04-22
16	Cefprozil granules (Lihong)	Hainan Simcere	Package	ZL201430253756.8	Appearance design	2014-07-24	2024-07-23

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
17	Aldioxa tablets (OUDJIA)	Hainan Simcere	Package	ZL201430253826.X	Appearance design	2014-07-24	2024-07-23
18	Hydrotalcite chewable tablets (DINGAN)	Hainan Simcere	Package	ZL201430253620.7	Appearance design	2014-07-24	2024-07-23
19	Trazodone hydrochloride tablets (Ancozy)	Jiangsu Simcere	Package (trazodone hydrochloride tablets – Ancozy)	ZL201730381033.X	Appearance design	2017-08-18	2027-08-17
20	Bortezomib for injection (Enlength)	Simcere Pharmaceutical; Jiangsu Simcere	Package (Bortezomib for injection – Enlength)	ZL201930593904.3	Appearance design	2019-10-30	2029-10-29
21	ANLIQING	Hainan Simcere; Jiangsu Simcere	Package (Meloxicam table – ANLIQING)	ZL201930598461.7	Appearance design	2019-10-31	2029-10-30

(iii) Patents concerning our pipeline products

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
1	PEG-ENDO (Pegylated recombinant human endostatin for injection)	Jiangsu Simcere	Endostatin biological activity detection method	ZL201510092378.3	Invention	2015-03-02	2035-03-01
2	PEG-ENDO (Pegylated recombinant human endostatin for injection)	Jiangsu Simcere	Method for measuring free polyethyleneglycol content in sample or products	ZL200910025005.9	Invention	2009-02-16	2029-02-15

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
3	PEG-ENDO (Pegylated recombinant human endostatin for injection)	Jiangsu Simcere; Shandong Simcere; China Pharmaceutical University	Modified recombinant human endostatin and application thereof	ZL201510333514.3	Invention	2007-09-05	2027-09-04
4	Bendamustine hydrochloride for injection	Jiangsu Simcere	Bendamustine hydrochloride mannitol ester and preparation method and application	ZL201410341785.9	Invention	2014-07-17	2034-07-16
5	Bendamustine hydrochloride for injection	Jiangsu Simcere	Preparation method of hydrochloric acid gamma-hydroxy bendamustine	ZL201010234591.0	Invention	2010-07-23	2030-07-22
6	Bendamustine hydrochloride for injection	Jiangsu Simcere; Simcere Pharmaceutical	Preparation method and applications of bendamustine hydrochloride dimer	ZL201410188275.2	Invention	2014-05-06	2034-05-05
7	Docetaxel polymeric micelles for injection	Jiangsu Simcere	Novel method for preparing indissoluble medicaments liposome preparations	ZL200810019877.X	Invention	2008-03-20	2028-03-19
8	Docetaxel polymeric micelles for injection	Jiangsu Simcere	Docetaxel medical composition for injection and preparation method thereof	ZL200710132056.2	Invention	2007-09-20	2027-09-19
9	Docetaxel polymeric micelles for injection	Jiangsu Simcere	Preparation of docetaxel long-circulating liposome and freeze-dried powder injection thereof	ZL200710023587.8	Invention	2007-06-11	2027-06-10
10	Docetaxel polymeric micelles for injection	Jiangsu Simcere; Simcere Pharmaceutical	Sulfo-taxane derivative and preparation method and application thereof	ZL200910035934.8	Invention	2009-10-14	2029-10-13

No.	Related	Name of	Patent Name	Patent Number	Class of	Application	
	Products of	Registered				Patent	Date
	Our Group	Proprietor					
11	Sevacizumab (Humanized anti-VEGF monoclonal antibody for injection)	Jiangsu Simcere	Anti-VEGF antibody containing pharmaceutical composition	ZL201210156166.3	Invention	2012-05-17	2032-05-16
12	Sevacizumab (Humanized anti-VEGF monoclonal antibody for injection)	Jiangsu Simcere; Apexigen	Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody	ZL201080018409.6	Invention	2010-08-27	2030-08-26
13	Lenvatinib mesilate capsules	Jiangsu Simcere	Synthesis method of important pharmaceutical and chemical intermediate 4-amino-3- chlorophenol	ZL201510779481.5	Invention	2015-11-13	2035-11-12
14	Y-2 sublingual tablets	Simcere Pharmaceutical; Yantai YenePharma Technology Co., Ltd.; Beijing Tiantan Hospital, Capital Medical University	Sublingual pharmaceutical composition of edaravone and (+)-2- borneol	ZL201780048512.7	Invention	2017-08-23	2037-08-22
15	CD19 CAR T-cell therapy	Shanghai Xianbo	Chimeric antigen receptor modified T cell and its use	ZL201510324558.X	Invention	2015-06-12	2035-06-11

(iv) Patents concerning our manufacturing facilities

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
1	Hainan Simcere	Dust removal device of filling mechanism of Diosmectite dispensing machine	ZL201920614314.9	Utility model	2019-04-30	2029-04-29
2	Hainan Simcere	Column mixer for making Naftopidil tablets	ZL201822181752.9	Utility model	2018-12-25	2028-12-24
3	Shandong Simcere	New type of air capture hood for anemometers	ZL201921076958.3	Utility model	2019-07-10	2029-07-09
4	Shandong Simcere	Recirculation-based sewage treatment device	ZL201921076105.X	Utility model	2019-07-10	2029-07-09
5	Shandong Simcere	Multi-channel sewage automatic sampling control circuit and its controlled automatic sampling device	ZL201921076040.9	Utility model	2019-07-10	2029-07-09
6	Shandong Simcere	Air return for easy daily cleaning	ZL201921075918.7	Utility model	2019-07-10	2029-07-09
7	Shandong Simcere	Equipment for urea crystal recovery	ZL201921076957.9	Utility model	2019-07-10	2029-07-09
8	Shandong Simcere	Clamping device for industrial sampling	ZL201921075961.3	Utility model	2019-07-10	2029-07-09
9	Shandong Simcere	Control system for over-standard humidity protection in clean area	ZL201921076003.8	Utility model	2019-07-10	2029-07-09
10	Shandong Simcere	Control circuit of electric continuously adjustable air valve	ZL201921076001.9	Utility model	2019-07-10	2029-07-09
11	Shandong Simcere	Calibration device for thermometer detection	ZL201921076096.4	Utility model	2019-07-10	2029-07-09
12	Shandong Simcere	Pipeline for pharmacy with temperature-detecting device on line sterilizes	ZL201821762929.8	Utility model	2018-10-30	2028-10-29
13	Shandong Simcere	High tightness stop valve	ZL201821677119.2	Utility model	2018-10-17	2028-10-16
14	Shandong Simcere	High-efficient laborsaving joint sealing platform	ZL201821677120.5	Utility model	2018-10-17	2028-10-16
15	Shandong Simcere	Rust-proof and dust-proof device for pharmaceutical weighing area	ZL201821635915.X	Utility model	2018-10-09	2028-10-08

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
16	Shandong Simcere	Novel plant substrate cultivation device	ZL201821635914.5	Utility model	2018-10-09	2028-10-08
17	Shandong Simcere	Paper collecting device of miniprinter	ZL201821635943.1	Utility model	2018-10-09	2028-10-08
18	Shandong Simcere	Bracket isolator for sterilizing pharmaceutical filling appliance	ZL201821635942.7	Utility model	2018-10-09	2028-10-08
19	Shandong Simcere	Fan filter unit with operation monitoring function	ZL201821635941.2	Utility model	2018-10-09	2028-10-08
20	Shandong Simcere	Pharmaceutical container pyrogen cleaning device	ZL201821635913.0	Utility model	2018-10-09	2028-10-08
21	Shandong Simcere	Automatic flowing back control circuit of waste liquid trap	ZL201821635944.6	Utility model	2018-10-09	2028-10-08
22	Shandong Simcere	Reinforced concrete water pipe cut-off equipment	ZL201721513537.3	Utility model	2017-11-14	2027-11-13
23	Shandong Simcere	Aseptic sample of fermentation cylinder and sample receiving system	ZL201720559592.X	Utility model	2017-05-18	2027-05-17
24	Shandong Simcere	Aseptic filtration monitoring system	ZL201720559441.4	Utility model	2017-05-18	2027-05-17
25	Shandong Simcere	Reaction type filling, loading system	ZL201620944205.X	Utility model	2016-08-25	2026-08-24
26	Shandong Simcere	Clean district personnel pass in and out automatic identification monitored control system	ZL201620942469.1	Utility model	2016-08-25	2026-08-24
27	Shandong Simcere	Airtight broken fungi tank	ZL201620943728.2	Utility model	2016-08-25	2026-08-24
28	Shandong Simcere	Full-automatic solution purification system	ZL201620944236.5	Utility model	2016-08-25	2026-08-24
29	Shandong Simcere	Ozone disinfection automatic system	ZL201620943100.2	Utility model	2016-08-25	2026-08-24
30	Shandong Simcere	Light concentrates timing control and mistake to go into self-closing circuit and controlling means thereof	ZL201520887092.X	Utility model	2015-11-06	2025-11-05
31	Shandong Simcere	Electrode auxiliary stand	ZL201520886935.4	Utility model	2015-11-06	2025-11-05

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
32	Shandong Simcere	Liquid soaks storage box for filter core	ZL201520882264.4	Utility model	2015-11-06	2025-11-05
33	Shandong Simcere	Stoste bucket rack	ZL201520882249.X	Utility model	2015-11-06	2025-11-05
34	Shandong Simcere	Stainless steel frame is prevented emptying by triangular flask	ZL201520882370.2	Utility model	2015-11-06	2025-11-05
35	Wuhu Simcere	Demoulding device applicable to implants drugs unloading machine	ZL201921706304.4	Utility model	2019-10-12	2029-10-11
36	Wuhu Simcere	Counting device applicable to auto subpackage of implants	ZL201921706284.0	Utility model	2019-10-12	2029-10-11
37	Wuhu Simcere	Incubator holder suitable for the storage of the bacteria collector during the implant testing	ZL201921101286.7	Utility model	2019-07-15	2029-07-14
38	Wuhu Simcere	Sample bottle for the implant testing process	ZL201921101287.1	Utility model	2019-07-15	2029-07-14
39	Wuhu Simcere	Pin remover suitable for implant compression molding process	ZL201821756776.6	Utility model	2018-10-29	2028-10-28
40	Wuhu Simcere	Temperature probe calibration clamp suitable for implant temperature monitoring	ZL201821756778.5	Utility model	2018-10-29	2028-10-28
41	Wuhu Simcere	Feeding device suitable for cleaning implant mold	ZL201821714137.3	Utility model	2018-10-23	2028-10-22
42	Wuhu Simcere	The workbench is suitable for implant filling	ZL201821714140.5	Utility model	2018-10-23	2028-10-22
43	Wuhu Simcere	The device is suitable for sub-packaging implant powder in inner bag	ZL201821714133.5	Utility model	2018-10-23	2028-10-22
44	Wuhu Simcere	The sealing structure is suitable for fluorouracil implant sterilizer	ZL201821714189.0	Utility model	2018-10-23	2028-10-22
45	Wuhu Simcere	The material receiving device is suitable for implant electronic supervision code tagging equipment	ZL201821714162.1	Utility model	2018-10-23	2028-10-22

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
46	Wuhu Simcere	Vibration feeder suitable for in implant production process	ZL201720966492.9	Utility model	2017-08-04	2027-08-03
47	Wuhu Simcere	Medicine grain filling device suitable for packer preface in implant	ZL201720966422.3	Utility model	2017-08-04	2027-08-03
48	Wuhu Simcere	Ration pressing sprayer suitable for implant inspection process culture medium filling equipment	ZL201720966506.7	Utility model	2017-08-04	2027-08-03
49	Wuhu Simcere	Equipment suitable for culture medium quantitative filling among fluorouracil implant inspection process	ZL201720966572.4	Utility model	2017-08-04	2027-08-03
50	Wuhu Simcere	Be applied to solid medicine article shedder of implant production field	ZL201620754798.3	Utility model	2016-07-18	2026-07-17
51	Wuhu Simcere	Many probe calibration constant temperature plug-in components devices suitable for implant preparation process	ZL201620736626.3	Utility model	2016-07-13	2026-07-12
52	Wuhu Simcere	Automation of being applied to electronic monitoring code coding collection system box-packed putting that fall	ZL201620650989.5	Utility model	2016-06-28	2026-06-27
53	Wuhu Simcere	Material transfer device suitable for implant press mold process	ZL201520564571.8	Utility model	2015-07-28	2025-07-27
54	Wuhu Simcere	Cleaning equipment suitable for implant mould	ZL201520560235.6	Utility model	2015-07-28	2025-07-27

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
55	Wuhu Simcere	A testing arrangement that is used for implant workshop to subside fungus	ZL201520484852.2	Utility model	2015-07-03	2025-07-02
56	Wuhu Simcere	Belt cleaning device suitable for implant endocyst material	ZL201520485729.2	Utility model	2015-07-03	2025-07-02
57	Wuhu Simcere	Material receiving device suitable for implant demolding process	ZL201420330401.9	Utility model	2014-06-19	2024-06-18
58	Wuhu Simcere	Material receiving device suitable for horizontal type labeling machine	ZL201420323219.0	Utility model	2014-06-17	2024-06-16
59	Wuhu Simcere	Washing device suitable for implant molds	ZL201420319762.3	Utility model	2014-06-16	2024-06-15
60	Wuhu Simcere	Adjusting device suitable for thermal coding machine	ZL201420319781.6	Utility model	2014-06-16	2024-06-15
61	Wuhu Simcere	Sampling device suitable for high-temperature liquid	ZL201420304502.9	Utility model	2014-06-09	2024-06-08
62	Wuhu Simcere	Automatic ultraviolet lamp start-stop control circuit	ZL201320009427.9	Utility model	2013-01-09	2023-01-08
63	Wuhu Simcere	Fixture suitable for multi-detector temperature calibration	ZL201220426275.8	Utility model	2012-08-27	2022-08-26
64	Wuhu Simcere	Pharmaceutical equipment suitable for implant mold pressing procedure	ZL201510460491.2	Invention	2015-07-28	2035-07-27

(v) *Other general patents⁽¹⁾*

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
1	Hainan Sincere	Medicine composition for treating upper respiratory tract infection and its preparation process	ZL200410094514.4	Invention	2004-10-30	2024-10-29
2	Jiangsu Sincere	Solid preparation of azilsartan and levamlodipine besylate composition and preparation method of solid preparation	ZL201510766656.9	Invention	2015-11-11	2035-11-10
3	Jiangsu Sincere	Crystallized polycrystalline substances of quinazoline derivative hydrochloride	ZL201510274335.7	Invention	2015-05-26	2035-05-25
4	Jiangsu Sincere	Thieno-[3,2-c] pyridine type compound as well as preparation method and application thereof	ZL201410119546.9	Invention	2014-03-27	2034-03-26
5	Jiangsu Sincere	Fused heterocycle compound as Bruton kinases inhibitor	ZL201310211840.8	Invention	2013-05-30	2033-05-29
6	Jiangsu Sincere	Bicyclic heterocyclic amine Hedgehog signal pathway inhibitor	ZL201310198730.2	Invention	2013-05-24	2033-05-23
7	Jiangsu Sincere	Bruton's kinase inhibitor	ZL201310192167.8	Invention	2013-05-22	2033-05-21
8	Jiangsu Sincere	Vilazodone hydrochloride composition and preparation method thereof	ZL201310146602.3	Invention	2013-04-24	2033-04-23
9	Jiangsu Sincere	Medicinal compound as neuroprotective agent	ZL201310080526.0	Invention	2013-03-13	2033-03-12
10	Jiangsu Sincere	Pyrazolo [3,4-d] pyrimidine compounds and preparation method thereof	ZL201310055425.8	Invention	2013-02-21	2033-02-20

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
					Date	Expiry Date
11	Jiangsu Simcere	Dihydropyran pyrimidine derivatives and pharmaceutical application thereof	ZL201310006146.2	Invention	2013-01-08	2033-01-07
12	Jiangsu Simcere	Pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors	ZL201210529962.7	Invention	2012-12-10	2032-12-09
13	Jiangsu Simcere	Novel synthetic method of prasugrel free base	ZL201210460819.7	Invention	2012-11-16	2032-11-15
14	Jiangsu Simcere	Thienoimidazole-like derivatives and applications thereof	ZL201210460829.0	Invention	2012-11-16	2032-11-15
15	Jiangsu Simcere	Pyrazolopyridine derivatives for inhibiting activity of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase	ZL201210461087.3	Invention	2012-11-15	2032-11-14
16	Jiangsu Simcere	Substituted furan-piperidine derivative and application thereof	ZL201210369245.2	Invention	2012-09-28	2032-09-27
17	Jiangsu Simcere	Method of preparing vilazodone and intermediate thereof	ZL201210335254.X	Invention	2012-09-11	2032-09-10
18	Jiangsu Simcere	Azilsartan polymorphic substance and preparation method thereof	ZL201210288384.2	Invention	2012-08-14	2032-08-13
19	Jiangsu Simcere	Method for preparing vilazodone and intermediate thereof	ZL201210254543.7	Invention	2012-07-20	2032-07-19
20	Jiangsu Simcere	Hydrogenated acridine derivative and application thereof	ZL201210230828.7	Invention	2012-07-04	2032-07-03
21	Jiangsu Simcere	Compound taken as potassium channel regulator	ZL201210224002.X	Invention	2012-06-29	2032-06-28

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
					Date	Expiry Date
22	Jiangsu Simcere	5-Amino-1,4-dihydro-1,8-naphthyridine derivatives and pharmaceutical compositions as well as uses thereof	ZL201210104212.5	Invention	2012-04-10	2032-04-09
23	Jiangsu Simcere	One type of benzofuran derivatives and medical application thereof	ZL201210104623.4	Invention	2012-04-10	2032-04-09
24	Jiangsu Simcere	Methanol solvate of quinazoline intermediate and preparation method thereof	ZL201210049553.7	Invention	2012-02-29	2032-02-28
25	Jiangsu Simcere	Piperazine compound and application thereof	ZL201210024813.5	Invention	2012-02-06	2032-02-05
26	Jiangsu Simcere	Fused heterocycle derivative and application thereof	ZL201110460766.4	Invention	2011-12-31	2031-12-30
27	Jiangsu Simcere	Synthesis method for 2,7-naphthyridine-1(2H)-ketone	ZL201110407677.3	Invention	2011-12-09	2031-12-08
28	Jiangsu Simcere	Pyrimidine compounds and application thereof	ZL201110361661.3	Invention	2011-11-15	2031-11-14
29	Jiangsu Simcere	2,7-naphthyridine derivative, and preparation method and application thereof	ZL201110262624.7	Invention	2011-09-06	2031-09-05
30	Jiangsu Simcere	Method for preparing imatinib methylolsulfonate alpha crystal through inverse solvent recrystallization method	ZL201110211545.3	Invention	2011-07-27	2031-07-26
31	Jiangsu Simcere	Inhibitor of benzoylammonia histone deacetylase	ZL201110132750.0	Invention	2011-05-20	2031-05-19
32	Jiangsu Simcere	A new preparation method for Dasatinib N-06 crystal form	ZL201110041185.7	Invention	2011-02-21	2031-02-20
33	Jiangsu Simcere	New preparation method of Lenalidomide B crystal form	ZL201110039831.6	Invention	2011-02-17	2031-02-16

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
					Date	Expiry Date
34	Jiangsu Simcere	Preparation method of pyrrole derivative and application thereof	ZL201110027560.2	Invention	2011-01-26	2031-01-25
35	Jiangsu Simcere	Application of antineoplastic constituent compound in solanum nigrum	ZL201110005350.3	Invention	2011-01-12	2031-01-11
36	Jiangsu Simcere	Compound, and preparation method and application thereof	ZL201010604750.1	Invention	2010-12-23	2030-12-22
37	Jiangsu Simcere	Benzamide histone deacetylase inhibitor	ZL201010564029.4	Invention	2010-11-29	2030-11-28
38	Jiangsu Simcere	Dasatinib solvate and preparation method thereof	ZL201010561241.5	Invention	2010-11-26	2030-11-25
39	Jiangsu Simcere	Compound and application thereof as L-calcium channel retarder or/and acetylcholinesterase inhibitor	ZL201010546303.5	Invention	2010-11-15	2030-11-14
40	Jiangsu Simcere	Preparation method for crystal form Gefitinib Form 1	ZL201010515608.X	Invention	2010-10-14	2030-10-13
41	Jiangsu Simcere	Preparation method of Erlotinib hydrochloride with crystal form A	ZL201010274216.9	Invention	2010-09-07	2030-09-06
42	Jiangsu Simcere	Polysaccharide sulfate fragment (PSC), preparation method and application thereof	ZL201010231317.8	Invention	2010-07-20	2030-07-19
43	Jiangsu Simcere	New application of thio-taxane derivatives	ZL201010156619.3	Invention	2010-04-27	2030-04-26
44	Jiangsu Simcere	Dipeptide boric acid consisting of carboxylic acid and beta amino acid, and ester compound, preparation method and usage thereof	ZL200910034130.6	Invention	2009-09-01	2029-08-31
45	Jiangsu Simcere	Quinazoline compound and application thereof	ZL200910032700.8	Invention	2009-06-30	2029-06-29

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
46	Jiangsu Simcere	New method for preparing 1-substituted-2,2-dimethoxyethylamine hydrochloride	ZL200910031079.3	Invention	2009-04-27	2029-04-26
47	Jiangsu Simcere	Recombinant fusion protein and preparing method and application thereof	ZL200810242790.9	Invention	2008-12-30	2028-12-29
48	Jiangsu Simcere	Novel natural imidazole formic acid derivates, preparation method and use thereof	ZL200810155974.1	Invention	2008-10-22	2028-10-21
49	Jiangsu Simcere	Novel technique for synthesizing toroid quinazoline protein tyrosine kinase restrainer	ZL200810024518.3	Invention	2008-03-26	2028-03-25
50	Jiangsu Simcere	Novel toosendan fruit peel extract	ZL200810020388.6	Invention	2008-03-04	2028-03-03
51	Jiangsu Simcere	Method for removing benzyl from quinazoline molecules containing halogens	ZL200710191489.5	Invention	2007-12-20	2027-12-19
52	Jiangsu Simcere	Method for preparing pinane diol ester under ZnCl ₂ catalysis	ZL200710191693.7	Invention	2007-12-14	2027-12-13
53	Jiangsu Simcere	Meliacarpinin derivatives, preparation method and use thereof	ZL200610096779.7	Invention	2006-10-16	2026-10-15
54	Jiangsu Simcere	Large scale preparation method for 3-[2-(dimethylamino)ethyl]-N-methyl-1-hydro-indoly-5-methanesulfonamide	ZL200610038045.3	Invention	2006-01-26	2026-01-25
55	Jiangsu Simcere	Chinese traditional medicine for preventing and treating osteoporosis and its preparation process	ZL200310112783.4	Invention	2003-12-26	2023-12-25

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application	
					Date	Expiry Date
56	Jiangsu Simcere	Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process	ZL200310106409.3	Invention	2003-11-24	2023-11-23
57	Shandong Simcere	Targeted interleukin fusion protein preparation method and use thereof	ZL201010185503.2	Invention	2010-05-28	2030-05-27
58	Jiangsu Simcere; Shandong Simcere	Preparation method of tumor necrosis factor related apoptosis induction ligand fusion protein	ZL201310089727.7	Invention	2013-06-05	2033-06-04
59	Jiangsu Simcere; Simcere Pharmaceutical	Pharmaceutical composition and application of same in preparation of medicines used for treating scalds	ZL201310087109.9	Invention	2013-03-18	2033-03-17
60	Jiangsu Simcere; Simcere Pharmaceutical	Pharmaceutical composition and its application in preparation of drugs treating scalds	ZL201310082606.X	Invention	2013-03-15	2033-03-14
61	Jiangsu Simcere; Simcere Pharmaceutical	One type of benzimidazole derivatives and application thereof	ZL201210106099.4	Invention	2012-04-11	2032-04-10
62	Jiangsu Simcere; Simcere Pharmaceutical	Phthalazine-like derivative and application thereof	ZL201210059422.7	Invention	2012-03-08	2032-03-07
63	Jiangsu Simcere; Simcere Pharmaceutical	Composition of 2,4-disulfonylalpha-phenyl-tert-butyl-nitrone and 2-camphenol	ZL201210055939.9	Invention	2012-03-06	2032-03-05
64	Jiangsu Simcere; Simcere Pharmaceutical	Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases	ZL201110326844.1	Invention	2011-10-25	2031-10-24

No.	Name of Registered Proprietor		Patent Name	Patent Number	Class of Patent	Application	
	Patent Name	Patent Number				Date	Expiry Date
65	Jiangsu Sincere; Sincere Pharmaceutical	Novel preparation method for Beta crystal type of Imatinib methane sulfonate	ZL201110043912.3	Invention	2011-02-23	2031-02-22	
66	Jiangsu Sincere; Sincere Pharmaceutical	Novel synthesis method for pyrrole derivatives	ZL201110024849.9	Invention	2011-01-24	2031-01-23	
67	Jiangsu Sincere; Sincere Pharmaceutical	Dipeptide boronic acids consisting of beta amino acids, ester compounds and preparation methods and uses thereof	ZL200810235724.9	Invention	2008-12-04	2028-12-03	
68	Jiangsu Sincere; Hainan Sincere	Method for preparing pyrrolidine dispiros compound intermediate	ZL200810124761.2	Invention	2008-09-02	2028-09-01	
69	Jiangsu Sincere; Wuhu Sincere	Camptothecin derivative, and preparation and use thereof	ZL200810019321.0	Invention	2008-01-03	2028-01-02	
70	Jiangsu Sincere; Wuhu Sincere	Oxazino camptothecin derivative, preparation and use thereof	ZL200710132953.3	Invention	2007-10-09	2027-10-08	
71	Jiangsu Sincere; Sincere Pharmaceutical	Aminochlorodipin, irbesartan compound preparation	ZL03150996.7	Invention	2003-09-19	2023-09-18	
72	Sincere Biology; The General Hospital of Shenyang Military of PLA	Preparation and application of recombinant human CREG-Fc fusion protein	ZL201811060510.2	Invention	2018-09-12	2038-09-11	
73	Jiangsu Sincere; Nanjing Xinnuotai Pharmaceutical Co., Ltd.	Peptidyl boronic acid, ester compound thereof, preparation method of peptidyl boronic acid and ester compound thereof, and use of peptidyl boronic acid and ester compound thereof	ZL200810022815.4	Invention	2008-07-30	2028-07-29	

No.	Name of Registered Proprietor	Patent Name	Patent Number	Class of Patent	Application Date	Expiry Date
74	Jiangsu Simcere; Chen Guoqing; Nanjing Aidecheng Pharmaceutical Technology Co., Ltd.	Spiro compounds and methods of use	ZL200780001719.5	Invention	2007-01-14	2027-01-13
75	Hainan Simcere	Package (Sumatriptan Succinate Tablets – Youshu) (琥珀酸舒馬普坦片-尤舒)	ZL201530112215.8	Appearance design	2015-04-23	2025-04-22
76	BCY Pharm	Pentacyclic triterpenoid compound providing an acetyl-CoA carboxylase 1 (ACC1) protein regulating effect, and uses thereof	ZL201510744150.8	Invention	2015-11-05	2035-11-04
77	BCY Pharm	A pentacyclic triterpenoid compound with modified structure and preparation method and application thereof	ZL201480065401.3	Invention	2014-11-18	2034-11-17
78	BCY Pharm	A pentacyclic triterpenoid compound with modified structure and preparation method and application thereof	ZL201310623314.2	Invention	2013-11-30	2033-11-29
79	BCY Pharm	Composition for treating psoriasis and preparation method thereof	ZL201210567434.0	Invention	2012-12-25	2032-12-24

Note:

- (1) These registered patents were developed during the process of our ground R&D work and have not been applied to any of our products as of the Latest Practicable Date.

As of the Latest Practicable Date, we have registered the following patents outside the PRC:

(i) *Patents concerning our major products*

Related Products of No.	Our Group	Name of Registered Proprietor	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾	Expiry Date ⁽³⁾
1	Endostar	Shandong Simcere	N-terminal modified recombinant human endostatin and its production	United States	US7078485	Invention	2002-12-05	2023-09-21

(ii) *Patents concerning our other existing products*

Related Products of No.	Our Group	Name of Registered Proprietor	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾	Expiry Date ⁽³⁾
1	Sanbexin	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	United States	US10206905	Invention	2016-06-08	2036-06-07
2	Sanbexin	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Japan	JP6450887	Invention	2016-06-08	2036-06-07
3	Sanbexin	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Australia	AU2016276488	Invention	2016-06-08	2036-06-07
4	Sanbexin	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Canada	CA2985219	Invention	2016-06-08	2036-06-07

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾	Expiry Date ⁽³⁾
5	Sanbexin	Jiangsu Simcere	Pharmaceutical Composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases	United States	US8658684	Invention	2009-03-03	2030-04-07
6	Sanbexin	Jiangsu Simcere	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	Australia	AU2009221546	Invention	2009-03-03	2029-03-02
7	Sanbexin	Jiangsu Simcere	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	Canada	CA2716874	Invention	2009-03-03	2029-03-02
8	Sanbexin	Jiangsu Simcere	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	Europe	EP2255804	Invention	2009-03-03	2029-03-02
9	Sanbexin	Jiangsu Simcere	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	Hong Kong	HK1150390	Invention	2009-03-03	2029-03-02
10	Sanbexin	Jiangsu Simcere	A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases	Japan	JP5272023	Invention	2009-03-03	2029-03-02

(iii) Patents concerning our pipeline products

No.	Related Products of Our Group	Name of Registered Proprietor	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾	Expiry Date ⁽³⁾
1	PEG-ENDO (Pegylated recombinant human endostatin for injection)	Jiangsu Simcere	Modified recombinant human endostatin and uses thereof	United States	US8802824	Invention	2008-09-04	2031-04-23
2	PEG-ENDO (Pegylated recombinant human endostatin for injection)	Jiangsu Simcere; Shandong Simcere	Modified recombinant human endostatin and its application	Europe	EP2196477	Invention	2008-09-04	2028-09-03
3	Sevacizumab (Humanized anti-VEGF monoclonal antibody for injection)	Jiangsu Simcere; Apexigen	Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody	United States	US8986692	Invention	2010-08-27	2030-09-06
4	Sevacizumab (Humanized anti-VEGF monoclonal antibody for injection)	Jiangsu Simcere; Apexigen	Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody	Europe	EP2471814	Invention	2010-08-27	2030-08-26
5	Sevacizumab (Humanized anti-VEGF monoclonal antibody for injection)	Jiangsu Simcere; Apexigen	Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody	Japan	JP5738294	Invention	2010-08-27	2030-08-26

(iv) Other general patents ⁽⁴⁾

No.	Name of Registered Proprietor	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾	Expiry Date ⁽³⁾
1	Jiangsu Simcere	Salt form of tyrosine kinase inhibitor	United States	US9018242	Invention	2013-09-11 ⁽²⁾	2032-03-11
2	Jiangsu Simcere	3-Pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof	Europe	EP2123649	Invention	2007-12-03	2027-12-02
3	Jiangsu Simcere	3-Pyrrolo[B] cyclohexylene-2-dihydroindolinone derivatives and uses thereof	India	IN316087	Invention	2007-12-03	2027-12-02
4	Jiangsu Simcere	3-Pyrrolo-cycloxyridene-2-Dihydro-indolinone derivative and uses thereof	Japan	JP5542445	Invention	2007-12-03	2027-12-02
5	Jiangsu Simcere	3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof	United States	US8084621	Invention	2007-12-03	2027-12-02

Notes:

- (1) The application date of the patents registered in the United States refers to the date disclosed in the INID (Internationally agreed Numbers for the Identification of (bibliographic) Data) code (22). The application date of the patents registered in India and Hong Kong refers to the PCT application international filing date of the relevant patents.
- (2) The initial date of such patent's protection period is March 12, 2012.
- (3) The European patent protection period is 20 years in its country of entry into force.
- (4) These registered patents were developed during the process of our ground R&D work and have not been applied to any of our products as of the Latest Practicable Date.

As of the Latest Practicable Date, we have applied for the registration of the following patents in the PRC:

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
1	Jiangsu Simcere	Amoxicillin impurity and preparation method and application thereof	201811635285.0	Invention	2018/12/29
2	Jiangsu Simcere	Impurities of posaconazole and preparation method and application thereof	201811639953.7	Invention	2018/12/29

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
3	Jiangsu Simcere	Synthetic method of 3-n-butyl-1 (3H)-isobenzofuranone	201811638787.9	Invention	2018/12/29
4	Jiangsu Simcere	HPLC analysis method for related substances of bortezomib	201811640847.0	Invention	2018/12/29
5	Jiangsu Simcere	Low water activity amoxicillin trihydrate pharmaceutical composition and preparation method thereof	201811641757.3	Invention	2018/12/29
6	Jiangsu Simcere	3-(Dimethylamino(phenyl)methylene)-2-oxoindole-6-carboxylic acid methyl ester and preparation method and application thereof	201811614198.7	Invention	2018/12/27
7	Jiangsu Simcere	Lenvatinib impurity and preparation method and application thereof	201811614519.3	Invention	2018/12/27
8	Jiangsu Simcere	Composition and preparation method thereof	201811575510.6	Invention	2018/12/22
9	Jiangsu Simcere	3-butyl-1(3H)-isobenzofuranone sulfobutyl- β -cyclodextrin inclusion compound and preparation method and application thereof	201811576330.X	Invention	2018/12/22
10	Jiangsu Simcere	Pharmaceutical preparation and preparation method thereof	201811576358.3	Invention	2018/12/22
11	Jiangsu Simcere	Pharmaceutical composition	201811576456.7	Invention	2018/12/22
12	Jiangsu Simcere	Preparation method of lenvatinib intermediate	201811536337.9	Invention	2018/12/14
13	Jiangsu Simcere	Preparation method for ezetimibe composition	201611236051.X	Invention	2016-12-28
14	Jiangsu Simcere	Preparation method and application of etoricoxib impurity	201611219504.8	Invention	2016-12-26
15	Jiangsu Simcere	Preparation method of Anamorelin	201611213282.9	Invention	2016-12-23
16	Jiangsu Simcere	Preparation method and applications of two tipiracil impurities	201611181144.7	Invention	2016-12-20
17	Jiangsu Simcere	Synthesis and applications of edaravone impurity	201611181350.8	Invention	2016-12-20
18	Jiangsu Simcere	Preparation method and application of melphalan dimmer hydrochloride	201611156843.6	Invention	2016-12-15
19	Jiangsu Simcere	Preparation method of Etoricoxib crystal form V	201611156864.8	Invention	2016-12-15

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
20	Jiangsu Simcere	Tofacitinib citrate enteric-coated sustained-release pellet and preparation method thereof	201610988949.6	Invention	2016-11-10
21	Jiangsu Simcere	Memantine hydrochloride sustained-release pellet and preparation method thereof	201610735626.6	Invention	2016-08-26
22	Jiangsu Simcere	Solid Regorafenib dispersion and preparation method thereof	201610601416.8	Invention	2016-07-27
23	Jiangsu Simcere	Obeticholic acid composition and preparation method thereof	201610592221.1	Invention	2016-07-26
24	Jiangsu Simcere	Preparation method for Osimertinib	201610445669.0	Invention	2016-06-20
25	Jiangsu Simcere	Preparation method and application of 4-[(2-chloroethyl-2-ethoxy) amino]-L-phenylalanine hydrochloride	201610112196.2	Invention	2016-02-29
26	Jiangsu Simcere	Detection method for related substances in posaconazole	201510997088.3	Invention	2015-12-28
27	Jiangsu Simcere	Quick-release regorafenib pellet and preparation method thereof	201510999846.5	Invention	2015-12-28
28	Jiangsu Simcere	Preparation method of erlotinib hydrochloride impurities	201510970535.6	Invention	2015-12-22
29	Jiangsu Simcere	Preparation method and application of afatinib cis-isomer	201510889550.8	Invention	2015-12-07
30	Jiangsu Simcere	Obeticholic acid composition and preparation method thereof	201510882051.6	Invention	2015-12-03
31	Jiangsu Simcere	Regorafenib impurity preparation method	201510749838.5	Invention	2015-11-06
32	Jiangsu Simcere	Pramipexole hydrochloride sustained release preparation and preparation method thereof	201510542964.3	Invention	2015-08-28
33	Jiangsu Simcere	Nintedanib impurity and preparation method and application thereof	201410729582.7	Invention	2014-12-03
34	Jiangsu Simcere	A novel crystallographic form of ceritinib and preparation method thereof	201410714723.8	Invention	2014-11-29
35	Jiangsu Simcere	Preparation method and application of 4-[1-methyl-5-(2-chloroethyl-2-ethoxy)amino-2-benzimidazolyl] butyric acid hydrochloride	201410188102.0	Invention	2014-05-06
36	Jiangsu Simcere	Tofacitinib analog and preparation method and application thereof	201410101534.3	Invention	2014-03-19

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
37	Jiangsu Simcere	Compound as potassium channel modulator	201810024836.3	Invention	2012-09-27
38	Jiangsu Simcere	Application of anti-VEGF antibody	201210156115.0	Invention	2012-05-17
39	Shandong Simcere	Device for concentration-treating medical waste liquid and method thereof	201910664754.X	Invention	2019-07-23
40	Wuhu Simcere	Drug carrier of slow-release chemotherapy target preparation in tumor operation and preparation method thereof	201910508872.1	Invention	2019-06-13
41	Wuhu Simcere	Device applicable to implant powder inner subpackage	201811233380.8	Invention	2018-10-23
42	Jiangsu Simcere; Simcere Pharmaceutical	Mycophenolate mofetil capsule and preparation method thereof	201910051239.4	Invention	2019/1/21
43	Jiangsu Simcere; Simcere Pharmaceutical	Sevelamer carbonate pharmaceutical composition and preparation method thereof	201910051569.3	Invention	2019/1/21
44	Jiangsu Simcere; Shandong Simcere	Purification method of 3-n-butyl-1 (3H)-isobenzofuranone	201811639440.6	Invention	2018/12/29
45	Jiangsu Simcere; Simcere Biology	Combination primer for nested amplification and application thereof	201811618134.4	Invention	2018/12/28
46	Jiangsu Simcere; Simcere Biology	High-throughput method for constructing monoclonal antibody expression vector	201811618124.0	Invention	2018/12/28
47	Jiangsu Simcere; Simcere Pharmaceutical	HPLC method for detecting related substances in the side chain of Biapenem	201811590785.7	Invention	2018/12/25
48	Jiangsu Simcere; Shandong Simcere	Polyethylene glycol modified vascular endostatin preparation composition	201811584735.8	Invention	2018/12/24
49	Jiangsu Simcere; Hainan Simcere	ICP-MS detection method for soluble lead content in montmorillonite powder	201811550601.4	Invention	2018/12/18
50	Jiangsu Simcere; Hainan Simcere	Liquid chromatography method for determining clavulanic acid related substances in amoxicillin and clavulanate potassium pharmaceutical composition	201811437505.9	Invention	2018/11/28
51	Jiangsu Simcere; Hainan Simcere	Solid Rivaroxaban dispersion and preparation method thereof	201811131435.4	Invention	2018-09-27

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
52	Jiangsu Simcere; Simcere Pharmaceutical	Hydrochloride melphalan crystal form and preparation method and applications thereof	201710730165.8	Invention	2017-08-23
53	Jiangsu Simcere; Simcere Pharmaceutical	Preparation method of azacytidine	201710627067.1	Invention	2017-07-28
54	Jiangsu Simcere; Hainan Simcere	HPLC detection method of lauryl sodium sulfate in Ezetrol sample	201710467616.3	Invention	2017-06-20
55	Jiangsu Simcere; Hainan Simcere	HPLC detection method of lauryl sodium sulfate in cefaclor dry suspension sample	201710467614.4	Invention	2017-06-20
56	Jiangsu Simcere; Simcere Pharmaceutical	Photodegradation impurities of melphalan and salt thereof and HPLC detection method thereof	201710455236.8	Invention	2017-06-16
57	Jiangsu Simcere; Simcere Pharmaceutical	Applications of composition in preparation of drugs for treatment of concussion	201710029034.7	Invention	2017-01-16
58	Jiangsu Simcere; Simcere Pharmaceutical	Liquid chromatography method for separation and determination of palonosetron hydrochloride	201610864081.9	Invention	2016-09-28
59	Jiangsu Simcere; Hainan Simcere	Method for preparing diosmectite	201610817487.1	Invention	2016-09-12
60	Jiangsu Simcere; Simcere Pharmaceutical	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	201680029994.7	Invention	2016-06-08
61	Jiangsu Simcere; Hainan Simcere	Medicinal composition capable of preventing or treating inflammatory diseases	201610390779.1	Invention	2016-06-06
62	Jiangsu Simcere; Hainan Simcere	Medicinal composition capable of preventing or treating inflammatory diseases	201610390780.4	Invention	2016-06-06
63	Jiangsu Simcere; Simcere Pharmaceutical	An HPLC method for detecting N-(4-(benzyloxy)benzylidene) aniline in N-(4-(benzyloxy)benzylidene)-4-fluoroaniline	201610300721.3	Invention	2016-05-09
64	Jiangsu Simcere; Hainan Simcere	Iguratimod slow-release capsules and preparation method thereof	201510875704.8	Invention	2015-12-02
65	Jiangsu Simcere; Simcere Pharmaceutical	Application of pharmaceutical composition in preparation of medicines for treating kidney failure	201510752731.6	Invention	2015-11-06

No.	Applicant	Patent Name	Patent Number	Class of Patent	Application Date
66	Jiangsu Simcere; Simcere Pharmaceutical	Application of composition of 3-methyl-1-phenyl-2-pyrazoline-5-ketone and (+)2-borneol	201510753461.0	Invention	2015-11-06
67	Jiangsu Simcere; Simcere Pharmaceutical	Noxafil impurities and preparation methods thereof	201510753583.X	Invention	2015-11-06
68	Jiangsu Simcere; Simcere Pharmaceutical	Preparation method for pimavanserin	201510577381.4	Invention	2015-09-11
69	Jiangsu Simcere; Simcere Pharmaceutical	Nedaplatin impurity detection method	201510577425.3	Invention	2015-09-11
70	Jiangsu Simcere; Simcere Pharmaceutical	Pramipexole oxidated impurity, preparation and separation method and application thereof	201410748545.0	Invention	2014-12-09
71	Jiangsu Simcere; Simcere Pharmaceutical	Edaravone derivative and preparation and detection methods and application thereof	201810888177.8	Invention	2013-04-03
72	Jiangsu Simcere; Shandong Simcere; Simcere Biology	Endostatin subcutaneous injection	201811561734.1	Invention	2018/12/20
73	Jiangsu Simcere; Simcere Pharmaceutical; Wuhu Simcere	HPLC method for detecting cyclopropylamine in lenvatinib mesylate	201811458909.6	Invention	2018/11/30
74	Jiangsu Simcere; Hainan Simcere; Simcere Pharmaceutical	Posaconazole pharmaceutical composition for external use and preparation method and use thereof	201810732469.2	Invention	2018-07-05
75	Jiangsu Simcere; Simcere Pharmaceutical; Wuhu Simcere	Azacitidine and preparation method and application thereof	201710934163.0	Invention	2017-10-10
76	Jiangsu Simcere; Simcere Pharmaceutical; Wuhu Simcere	Azacitidine disaccharide impurity and preparation method and application thereof	201710933894.3	Invention	2017-10-10
77	Jiangsu Simcere; Zhejiang Provincial People's Hospital	Application of recombinant human endostatin in preparing drugs for treating ocular neovascular diseases	201410814133.2	Invention	2014-12-23

As of the Latest Practicable Date, we have applied for the registration of the following patents outside the PRC:

No.	Applicant	Patent Name	Place of Registration	Patent Number	Class of Patent	Application Date ⁽¹⁾
1	Jiangsu Simcere	Pyrimidine pyrazole compound as fourth-generation EGFR inhibitors	-	PCT/CN2019/113608	Invention	2019-10-28
2	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Hong Kong	HK18111444.9	Invention	2016-06-08
3	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Europe	EP16806843	Invention	2016-06-08
4	Jiangsu Simcere	Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis	Hong Kong	HK17113792.4	Invention	2016-06-08

Note:

- (1) The application date of the above patents refers to the PCT application international filing date of the relevant patents.

(c) Domain names

As of the Latest Practicable Date, we had registered the following domain names:

No.	Domain Names	Registered Owner	Registration Date	Expiry Date
1.	isimcere.com	Jiangsu Simcere	2008-08-12	2021-08-12
2.	simcere.com	Jiangsu Simcere	2016-09-09	2022-05-08
3.	bingli2019.com	Jiangsu Simcere	2018-12-28	2020-12-28
4.	simcere.tech	Jiangsu Simcere	2019-10-22	2029-10-23
5.	bcypso.com	BCY Pharm	2015-05-18	2021-05-18
6.	bcypharm.com	BCY Pharm	2016-11-17	2020-11-17

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of interest

(a) *Disclosure of interest of Directors and chief executive of our Company*

Immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), the interest or short position of our Directors or chief executives of our Company in the Shares, underlying shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interest or short positions which they were taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers to be notified to our Company and the Stock Exchange, once the Shares are listed, will be as follows:

(i) *Interests in our Company*

Name of Director/ Chief executive	Nature of interest	Number of Shares/ underlying shares interested	Approximate percentage of shareholding immediately following the Global Offering (assuming the Over-allotment Option is not exercised)
Mr. Ren ⁽¹⁾	Interest in controlled corporations/Interest of concert parties	2,035,922,965	78.13%
Mr. Zhao John Huan ⁽²⁾	Interest in controlled corporations	114,986,405	4.41%

Notes:

- (1) Immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), Mr. Ren, together with other Ultimate Controlling Shareholders will collectively and indirectly hold 2,035,922,965 Shares, including (i) 606,810,031 Shares and 1,196,009,986 Shares directly held by Artking and SPHL, respectively, both of which are companies controlled by our Ultimate Controlling Shareholders; and (ii) 112,141,578 Shares and 120,961,370 Shares directly held by EGG and FFI, respectively, both of which are companies controlled by Mr. Ren. By virtue of the SFO, as our Ultimate Controlling Shareholders are deemed to be persons acting in concert under the Takeovers Code, each of them is deemed to be interested in the Shares held by each other.

- (2) Immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), Premier Praise will directly hold 114,986,405 Shares. Premier Praise is held as to 82.22% by Hony Capital Fund V, L.P. The general partner of Hony Capital Fund V, L.P. is Hony Capital Fund V GP, L.P., whose general partner is Hony Capital Fund V GP Limited. Hony Capital Fund V GP Limited is wholly owned by Hony Group Management Limited, 80% equity interest of which is held by Hony Managing Partners Limited, which in turn is wholly owned by Exponential Fortune Group Limited. Exponential Fortune Group Limited is held as to 49% by Mr. Zhao John Huan and as to 51% by two other individuals who are Independent Third Parties, respectively. Therefore, Mr. Zhao John Huan is deemed to be interested in the Shares held by Premier Praise by virtue of the SFO.

(ii) *Interests in our associated corporations*

Name of Director/ Chief executive	Capacity/Nature of interest	Name of associated corporation	Approximate percentage of shareholding interest
Mr. Ren	Beneficial interest	Shanghai Xianbo	95%

(b) *Disclosure of interest of substantial Shareholders of our Company*

Save as disclosed in “Substantial Shareholders,” our Directors are not aware of any other person who will, immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), have an interest or short position in the Shares or underlying Shares of our Company which are required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying the rights to vote in all circumstances at the general meetings of our Company.

(c) *Disclosure of interests of the substantial shareholders of any member of our Group (other than our Company)*

So far as the Directors are aware, as of the Latest Practicable Date, the following person was interested in 10% or more of the nominal value of the share capital carrying rights to vote in all circumstances at general meetings of any member of the Group (other than us):

Name of shareholder	Name of member of our Group	Approximate percentage of shareholding
Mr. Wang Honglin	BCY Pharm	29.7%

2. Particulars of Directors' service contracts and letters of appointment

Each of Mr. Ren, Mr. Wan Yushan, Mr. Zhang Cheng and Mr. Tang Renhong, being our executive Directors, has entered into a service contract with our Company on October 8, 2020. Each service contract is for an initial term of three years commencing from the Listing Date. The service contracts may be renewed in accordance with our Articles of Association and the applicable laws, rules and regulations.

Each of Mr. Zhao John Huan, being our non-executive Director and Mr. Song Ruilin, Mr. Wang Xinhua and Mr. Wang Jianguo, being our independent non-executive Directors, has entered into a letter of appointment with our Company on October 8, 2020. Each letter of appointment is for an initial term of three years commencing from the Listing Date. The letters of appointment may be renewed in accordance with our Articles of Association and the applicable laws, rules and regulations.

3. Directors' remuneration

The aggregate amounts of remuneration (including fees, salaries, allowances, benefits in kind, discretionary bonuses, retirement scheme contributions and share-based payments) of our Directors recorded for the three years ended December 31, 2017, 2018, and 2019 and the six months ended June 30, 2020 were approximately RMB8.76 million, RMB2.57 million, RMB9.21 million and RMB10.81 million, respectively.

There was no arrangement under which a Director has waived or agreed to waive any emoluments for each of the three financial years immediately preceding the issue of this prospectus.

Save as disclosed in this prospectus, no other payments have been made or are payable for the years ended December 31, 2017, 2018 and 2019 and the six months ended June 30, 2020 by any member of our Group to any of our Directors.

During the Track Record Period, no remuneration was paid by us to, or receivable by, our Directors or the five highest paid individuals as an inducement to join or upon joining our Company. No compensation was paid by us to, or receivable by, our Directors, former Directors, or the five highest-paid individuals for each of the Track Record Period for the loss of any office in connection with the management of the affairs of any members of our Group.

It is estimated that remuneration equivalent to approximately RMB21.33 million in aggregate will be paid to the Directors (inclusive of benefits in kind but exclusive of any discretionary bonuses) by our Company for the year ending December 31, 2020, based on the arrangements currently in force.

4. Personal guarantees

Save as disclosed in this prospectus, our Directors have not provided personal guarantees in favor of lenders in connection with banking facilities granted or to be granted to any member of our Group.

5. Agency fees or commissions received

Save as disclosed in this prospectus, none of the Directors or any of the persons whose names are listed under the sub-section headed “– E. Other Information – 8. Consents of experts” below had received any commissions, discounts, agency fee, brokerages or other special terms in connection with the issue or sale of any capital of any member of our Group within the two years immediately preceding the date of this prospectus.

6. Disclaimers

Save as disclosed herein:

- (a) none of our Directors or the chief executive of our Company has any interest or short position in the Shares, underlying shares or debentures of our Company or any of its associated corporation (within the meaning of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers once the Shares are listed;
- (b) none of our Directors or any of the experts referred to under “– E. Other Information – 7. Qualification of experts” in this appendix has any direct or indirect interest in the promotion of our Company, or in any assets which have within the two years immediately preceding the date of this prospectus been acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (c) none of our Directors is materially interested in any contract or arrangement subsisting at the date of this prospectus which is significant in relation to the business of our Group;
- (d) none of our Directors has any existing or proposed service contracts with any member of our Group (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation));

- (e) taking no account of any Shares which may be taken up under the Global Offering, so far as is known to our Directors or chief executive of our Company, no person (not being a Director or chief executive of our Company) who will, immediately following the completion of the Global Offering, have an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of SFO or be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group; and
- (f) so far as is known to our Directors, none of our Directors, their respective close associates (as defined under the Listing Rules) or our Shareholders who are interested in more than 5% of the issued share capital of our Company has any interest in the five largest customers or the five largest suppliers of our Group.

D. PRE-IPO SHARE INCENTIVE SCHEME

1. Background

On July 31, 2014, SPHL adopted a pre-IPO share incentive scheme (the “**Pre-IPO Share Incentive Scheme**”), with a view to recognizing the contributions of our employees and to incentivize them to further promote our development. For details of the background of the Pre-IPO Share Incentive Scheme, please see Note 32(a) in the Accountants’ Report set out in Appendix I to this prospectus.

After granting of the restricted shares (the “**Awarded Shares**”) under the Pre-IPO Share Incentive Scheme, the Awarded Shares owned by certain original Participants (as defined below) were transferred to the designees of the Administrator (as defined below) or acquired by Excel Management due to the resignation from office of these original Participants or for other reasons. As such, with a view to granting the Awarded Shares to the new Participants, SPHL amended the Pre-IPO Share Incentive Scheme and made such grant to the new Participants on October 1, 2019. On April 4, 2020, Excel Management allotted and issued an aggregate of 111,572,260 shares to Assure Good, Great Good, Next Good and Promise Good, being the holding vehicles for the participants of the Pre-IPO Share Incentive Scheme (the “**Offshore SPVs**”). On the same date, Estera Services (Bermuda) Limited, the trustee of the Excel Management Trust, transferred all the equity interest it held in Excel Management, being 100,000 shares, to Promise Good.

The Pre-IPO Share Incentive Scheme is not subject to the provisions of Chapter 17 of the Listing Rules as the Pre-IPO Share Incentive Scheme does not involve the grant of options by our Company to subscribe for new Shares.

2. Participants and eligibility

The participants of the Pre-IPO Share Incentive Scheme (the “**Participants**”) are the members and candidates of our management team, core R&D personnel and personnel with outstanding contribution in project management and with other special contribution to our Group who are selected and approved by the board of directors of SPHL to receive the Awarded Shares.

3. Administration

The Pre-IPO Share Incentive Scheme is administered by the office of the board of directors of SPHL and the human resource department of our Group (the “**Administrator**”) which are authorised by the board of directors of SPHL. The Administrator shall have the authority to:

- (i) formulate the terms and conditions of the Awarded Shares granted;
- (ii) be responsible for the performance appraisal of the Participants;
- (iii) record the grant, transferring and redemption of the Awarded Shares in the management account;
- (iv) maintain the records of the documents in relation to the Pre-IPO Share Incentive Scheme;
- (v) report to the board of directors of SPHL in respect of the implementation of the Pre-IPO Share Incentive Scheme and grant of Awarded Shares thereunder; and
- (vi) interpret or amend the terms and conditions of the Pre-IPO Share Incentive Scheme.

4. Grant price of the Awarded Shares

For details of the grant price for each Awarded Shares, please see Note 32(a) in the Accountants’ Report set out in Appendix I to this prospectus.

5. Vesting Period

None of the Awarded Shares granted to the Participants shall be disposed within the vesting period (the “**Vesting Period**”) during which the Participants shall serve for our Group on a continuing basis. Please see Note 32(a) in the Accountants’ Report set out in Appendix I to this prospectus for further details.

6. Awarded Shares granted

As of the Latest Practicable Date, all of the Awarded Shares has been granted to 268 Participants, among which four are our Directors, and four are members of our senior management. The Awarded Shares granted under the Pre-IPO Share Incentive Scheme represent approximately 4.76% of the Company's issued share capital as of the Latest Practicable Date. The grant and vesting of the Awarded Shares granted pursuant to the Pre-IPO Share Incentive Scheme are in compliance with Rule 10.08 of the Listing Rules.

7. Restrictions on the Awarded Shares

If the Participants or the Offshore SPVs are subject to a lock-up period imposed by the relevant laws, regulations or rules, no Participants or the Offshore SPVs shall dispose the Awarded Shares and the Shares of our Company indirectly held through Excel Management and SPHL except as otherwise set forth in the Pre-IPO Share Incentive Scheme.

The board of directors of SPHL may cancel the eligibility of the Participants if such Participants have the following circumstances:

- (i) the breach of any applicable laws, regulations and professional ethics, leakage of national or corporate secrets, corruption, theft, misappropriation, bribe-taking, bribe-giving, negligence of duty, in violation of public order, professional morals and ethics, cessation of employment due to the violation of any non-disclosure agreement and employment agreement causing severe damage to the Group's interests and reputation (irrespective of the expiration of the Vesting Period or the listing progress of the Company);
- (ii) being dismissed by any company of our Group on the ground set out in the above paragraph (i) (irrespective of the expiration of the Vesting Period or the listing progress of the Company);
- (iii) physical disability, death, resignation or dismissal within the Vesting Period.

After the expiration of Vesting Period, the Participants may dispose the Awarded Shares on the following procedures:

- (i) if the Listing become unsuccessful or, after the Listing, the Shares held directly by the Excel Management or indirectly through SPHL are within the lock-up period imposed by relevant laws, regulations or rules, the Participants who wish to transfer the Awarded Shares ("**Transferor**") shall give a 30 day's prior notice to the Administrator. Subject to the approval of the Administrator, the transfer price will be determined based on arm's length negotiation with the Administrator.

- (ii) if the lock-up period imposed by relevant laws, regulations or rules on the Shares held by the Excel Management expires, the Awarded Shares may be disposed in accordance with the procedures set forth in paragraph (i) above or in accordance with the relevant law, regulations or rules.

E. OTHER INFORMATION

1. Estate duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

During the Track Record Period and up to the Latest Practicable Date, save as disclosed in this prospectus and so far as our Directors are aware, no litigation or claim of material importance (to our Group's financial condition or results of operation) is pending or threatened against any member of our Group.

3. Joint Sponsors

The Joint Sponsors has made an application on our behalf to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares in issue, the Shares to be issued as mentioned in this prospectus. All necessary arrangements have been made to enable such Shares to be admitted into CCASS.

Morgan Stanley Asia Limited satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules. Pursuant to Rule 3A.07 of the Listing Rules, China International Capital Corporation Hong Kong Securities Limited (“CICC”) has declared that as regards their relationship with our Company, they are not or do not expect to be independent because CICC Cayman, an affiliate of CICC, together with Industrial Bank Co., Ltd. Hong Kong Branch, had entered into a US\$110,000,000 term facility agreement dated 29 April 2019 with FFI and EGG, pursuant to which CICC Cayman's commitment was US\$20,000,000. Please see “History, Reorganization and Corporate Structure – Reorganization – Offshore Reorganization – Share Transfers of Our Shareholders – Share Transfer of Simcere Holding” for further details. In addition, China International Capital Corporation Limited, an affiliate of CICC, was also engaged by our Company in 2019 as the tutoring agency to provide guidance and preliminary compliance advice with regards to the requirements of CSRC and the relevant stock exchange. For further details, please refer to “History, Reorganization and Corporate Structure – PRC Listing Plan.” After taking into account the aforementioned relationships, CICC considered that such relationships would be reasonably considered to affect their independence in performing their duties as set out in Chapter 3A of the Listing Rules, or might reasonably give rise to a perception that their independence would be so affected, pursuant to Rule 3A.07(1) of the Listing Rules. The sponsors fee payable to the Joint Sponsors by our Company is USD500,000 each.

4. Preliminary expenses

The preliminary expenses incurred by our Company in connection with the Listing amounts to approximately USD11,616.

5. Promoter

We do not have any promoter for the purpose of the Listing Rules. Within the two years immediately preceding the date of this prospectus, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoter in connection with the Global Offering and the related transactions described in this prospectus.

6. Taxation of holders of Shares

(a) *Hong Kong*

(i) *Estate Duty*

The Revenue (Abolition of Estate Duty) Ordinance 2005 came into effect on February 11, 2006 in Hong Kong, pursuant to which estate duty ceased to be chargeable in Hong Kong in respect of the estates of persons dying on or after that date. No Hong Kong estate duty is payable and no estate duty clearance papers are needed for an application for a grant of representation in respect of holders of Shares whose death occur on or after February 11, 2006.

(ii) *Stamp Duty*

Dealing in the Shares will be subject to Hong Kong stamp duty. The current ad valorem rate of Hong Kong stamp duty is 0.1% on the higher of the consideration for or the market value of the Shares and it is charged on the purchaser on every purchase and on the seller on every sale of the Shares. In other words, a total stamp duty of 0.2% is currently payable on a typical sale and purchase transaction involving the Shares.

(iii) *Dividends*

No tax is imposed in Hong Kong in respect of dividends our Company pays to the Shareholders. Dividends paid to the Shareholders are free of withholding taxes in Hong Kong.

(iv) Capital gains and profits tax

No tax is imposed in Hong Kong in respect of capital gains from the sale of the Shares. Trading gains from the sale of the Shares by persons carrying on a business in Hong Kong, where such gains are sourced in Hong Kong and arise from such business, will be chargeable to Hong Kong profits tax.

(b) Consultation with professional advisors

Intending holders of the Shares are recommended to consult their professional advisors if they are in any doubt as to the taxation implications of subscribing for, purchasing, holding or disposing of or dealing in the Shares. It is emphasized that none of our Company, our Directors or the other parties involved in the Global Offering will accept responsibility for any tax effect on, or liabilities of, holders of Shares resulting from their subscription for, purchase, holding or disposal of or dealing in the Shares or exercise of any rights attaching to them.

7. Qualification of experts

The following are the qualifications of the experts who have given opinion or advice which are contained in this prospectus:

Name	Qualifications
Morgan Stanley Asia Limited	Licensed corporation to conduct Type 1 (dealing in securities), Type 4 (advising on securities), Type 5 (advising on futures contracts), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities as defined under the SFO
China International Capital Corporation Hong Kong Securities Limited	Licensed corporation to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) of the regulated activities as defined under the SFO
KPMG	Certified Public Accountants Public Interest Entity Auditor registered in accordance with the Financial Reporting Council Ordinance
Tian Yuan Law Firm	PRC legal advisors to our Company

Name	Qualifications
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant
Jones Lang LaSalle Corporate Appraisal and Advisory Limited	Independent property valuer

8. Consents of experts

Each of Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, KPMG, Tian Yuan Law Firm, Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. and Jones Lang LaSalle Corporate Appraisal and Advisory Limited has given and has not withdrawn its consent to the issue of this prospectus with the inclusion of its view, report and/or letter and/or legal opinion (as the case may be) and references to its name included herein in the form and context in which it respectively appears.

None of the experts named above has any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in our Company or any of our subsidiaries.

9. Bilingual prospectus

The English language and Chinese language versions of this prospectus are being published separately in reliance on the exemption provided in section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

10. Binding effect

This prospectus shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

11. Miscellaneous

- (a) save as disclosed in this prospectus, within the two years immediately preceding the date of this prospectus:
 - (i) no share or loan capital of our Company or any member of our Group had been issued or agreed to be issued or proposed to be fully or partly paid either for cash or a consideration other than cash;

- (ii) no commissions, discounts, brokerages or other special terms had been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any member of our Group;
- (iii) no commission had been paid or payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any share in our Company or any member of our Group;
- (b) save as disclosed in this prospectus, no share or loan capital of our Company or any member of our Group had been under option or agreed conditionally or unconditionally to be put under option;
- (c) save as disclosed in this prospectus, there are no founder, management or deferred shares, convertible debt securities nor any debentures in our Company or any member of our Group;
- (d) our Directors confirm that there has been no material adverse change in the financial or trading position of our Group since June 30, 2020 (being the date to which the latest audited consolidated financial statements of our Group were made up);
- (e) there has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this prospectus;
- (f) our Hong Kong register of members will be maintained by the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, in Hong Kong. All transfer and other documents of title of the Shares must be lodged for registration with and registered by our share register in Hong Kong;
- (g) all necessary arrangements have been made to enable the Shares to be admitted to CCASS;
- (h) no company within our Group is listed on any stock exchange or traded on any trading system at present, and our Group is not seeking or proposing to seek any listing of, or permission to deal in, the share or loan capital of our Company on any other stock exchange; and
- (i) there is no arrangement under which future dividends are waived or agreed to be waived.